VDAC1 oligomerization may enhance DDP-induced hepatocyte apoptosis by exacerbating oxidative stress and mitochondrial DNA damage

Xueqin Zhu¹, Lei Luo¹,², Yanyan Xiong¹, Nan Jiang¹, Yurun Wang¹, Yuan Lv¹ and Ying Xie¹

¹ Key Laboratory of Molecular Epidemiology of Hunan Province, School of Medicine, Hunan Normal University, Changsha, China
² Changsha Center for Disease Control and Prevention, Beijing, China

Keywords
4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid; apoptosis; cisplatin; hepatocyte; oligomerization; voltage-dependent anion channel 1

Correspondence
Y. Xie and Y. Lv, Key Laboratory of Molecular Epidemiology of Hunan Province, School of Medicine, Hunan Normal University, 371 Tongzipo Road, Changsha 410078, China
Tel: +8615973181205
E-mails: xieying@hunnu.edu.cn, 284792906@qq.com

Xueqin Zhu and Lei Luo contributed equally to this work.

(Received 24 August 2021, revised 9 November 2021, accepted 29 December 2021)

doi:10.1002/2211-5463.13359
Edited by Irene Díaz-Moreno

With the development of medical treatments, cisplatin (DDP)-based chemotherapy is a preferred treatment for a broad spectrum of cancers. Unfortunately, the clinical use of DDP is limited by its severe toxic side effects. Liver and kidney toxicities are the most common side effects and dose-limiting factor under DDP treatment and reduced therapeutic effect and life expectancy of patients. However, the exact mechanism of how to protect against liver toxicity has not been clarified clearly [1].

Abbreviations
COXI, complex I; DDP, cisplatin; DIDS, 4,4'-diisothiocyanate-2,2'-disulfonic acid; ECL, electrochemiluminescence; NAD⁺, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide reduced form; O₂⁻, mitochondrial superoxide anion radical; OD, optical density; pH, potential of hydrogen; PI, propidium iodide; ROS, reactive oxygen species; RPMI, Roswell Park Memorial Institute; RT, room temperature; VDAC1, voltage-dependent anion channel protein 1.
Generally, the interactions with purine residues to form DNA cross-linking complexes are considered as the major biological mechanism of DDP [2]. Mitochondria are the central for energy supply and signal transduction in hepatocytes, which also serves as targets for chemotherapeutic drug. If DNA damage repair fails, the mitochondrial-dependent apoptotic process is initiated [3]. When DNA damage and subsequent mitochondrial oxidative stress occurs, electron leakage from the respiratory chain gradually derives into superoxide anion free radical (O$_2^{-}$), hydroxyl radical, and hydrogen peroxide. Reactive oxygen species (ROS) further interact with DNA, lipids, and proteins and cause a cascade of mitochondrial damage and release of apoptotic factors, leading to mitochondria-dependent apoptosis [4]. Numerous studies have confirmed that antioxidants reduced DDP-induced hepatotoxicity by inhibiting oxidative stress, reducing inflammatory response and apoptosis [5–7].

Recently, the role of voltage-dependent anion channel protein 1 (VDAC1) in mitochondrial activity and cell apoptosis has attracted much attention. VDAC1 is an important channel for exchange of energy and substances between mitochondria and cells by regulates transport of anions, cations, ATP, and other metabolites [8]. Various apoptosis inducers, including staurosporine, curcumin, selenite, and arsenic oxide, induced formation of the VDAC dimer and oligomers [9]. Keinan N et al. also found that DDP induced VDAC1 oligomerization in HEK-293 cells at relatively high concentrations (40–50 μM) [10]. VDAC1 oligomer forms a pore large enough for the release of apoptosis-inducing factors, which activates the caspase cascade reaction and subsequently leads to apoptosis [11].

The well-known chloride channel blocker 4,4’-diisothiocyanatostilbene-2,2’-disulfonicacid (DIDS) was used to investigate the role of VDAC1 oligomerization in cytotoxicity. DIDS affects the activity of a number of transporters, and there is an extensive literature in support that DIDS can inhibit VDAC1 oligomerization. DIDS reversibly interacts with VDAC1 and inhibits its channel conductance and oligomerization [12]. Ben-Hail et al. demonstrated that VDAC1 undergoes oligomerization in response to cancer cell damage and mitochondrial oxidative stress, and DIDS and its analogs inhibited apoptosis via direct interaction with VDAC1 to inhibit its oligomerization and subsequent Cyto c release and apoptosis [11]. However, the role of VDAC1 oligomerization in hepatotoxicity exposed after DDP has not been illustrated.

The present study aims to further explore the potential effects of VDAC1 oligomerization on DDP-induced mitochondrial damage and apoptosis in L-02 hepatocytes, which provide scientific evidence for alleviating liver injury in patients undergoing chemotherapy.

### Materials and methods

#### Cell culture and treatment

L-02 cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. DDP (Merck, USA) and DIDS (MedChem Express, USA) were used in the experiments.

#### Cell apoptosis analysis

Cell apoptosis was detected by Annexin V-FITC/PI Apoptosis kit (Beijing Solarbio Technology Co., Ltd., China). In brief, 1 × 10$^5$ cells were resuspended in 100 μL supplied binding buffer and then stained with 5 μL FITC-conjugated Annexin V and 10 μL PI at RT for 15 min in darkness, according to the manufacturer’s protocol. The fluorescence intensities of the cells were detected by flow cytometer (ACEA Biosciences, USA). The Annexin V-FITC+/PI$^-$ cell population was regarded as normal, while Annexin V-FITC$^-$/PI$^+$ cells were taken as a measure of early apoptosis, Annexin V-FITC$^-$/PI$^+$ as late apoptosis, and Annexin V-FITC$^-$/PI$^+$ as necrosis.

#### Western blotting

Methods for Western blotting were performed as described previously [13]. All antibodies were purchased commercially: anti-Caspase-3 (Santa Cruz; sc-56053); anti-H2AX (Merck Millipore; 2391108); anti-NDUFB6 (Abcam, ab110244); anti-β-actin (GeneTex; GTX124502). After incubation with the secondary antibody, the protein bands were visualized with ECL detection (Invitrogen, USA) and a chemiluminescence imager (Minichem, China).

#### Measurement of intracellular ROS levels

The intracellular ROS levels were measured using a Reactive Oxygen Species Assay Kit (Beyotime Biotechnology, China) as described previously [13]. Following the treatment, cells were incubated with DCFH-DA for 20 min at 37 °C. Fluorescence was analyzed using a multifunctional enzyme labeling instrument (Molecular Devices, USA) with excitation at 488 nm and emission at 525 nm. The fluorescence intensity reflected the amount of ROS generated.

#### Detection of MitoSOX formation

Mitochondrial superoxide anion radicals (MitoSOX) were detected using MitoSOX™ Red mitochondrial superoxide indicator (Thermo Scientific, USA) as described previously.
5 nm MitoSOX working solution was added to cells and incubated at 37 °C for 10 min, protected from light. After washing, cells were detected with a multifunctional molecular device with excitation at 510 nm and emission at 580 nm.

**Comet assay**

The comet assay was performed using a reagent kit for single-cell gel electrophoresis ( Trevigen, Inc., Gathersburg, MD, USA) according to a modified method of Viera et al. [14]. Cells were trypsinized and collected, washed with PBS, and resuspended on PBS. Cells were added to melted LMA-garose (Trevigen) cooled to 37 °C at a ratio of 1 : 10 and pipetted onto a pre-warmed comet slide and spread evenly. Slides were then placed at 4 °C for 30 min to allow adherence of the agarose to the slides. The slides were then gently immersed in lysis solution overnight at 4 °C. Following lysis, the slides were immersed in 1 × Neutral Electrophoresis Buffer containing Tris base and sodium acetate (corrected to pH 9 with glacial acetic acid) for 30 min at 4 °C. The slides were electrophoresed at 21 V for 45 min at 4 °C in the neutral electrophoresis buffer and then immersed in DNA precipitation solution and 70% ethanol successively for 30 min each time. Then, slides were stained with DAPI and viewed using fluorescent microscopes. Comet measurement and quantitative analysis were performed using CASP software.

**Complex I enzyme activity assay**

Mitochondrial OXPHOS Complex I enzyme activity was determined using the Complex I Enzyme Activity Microplate Assay Kit ( Abcam109721; UK). The enzymatic activity was expressed as the change in absorbance (mOD) per minute, which was calculated by fitting the initial linear portion of each kinetic curve.

**Statistical analysis**

The results were calculated from quantitative data obtained from three replicate experiments. Statistical analysis was performed using ANOVA and LSD t-test in SPSS v20.0 software. The P-values ≤ 0.05 were considered significant.

**Results**

**DIDS antagonized DDP-induced apoptosis in L-02 hepatocytes**

We treated L-02 hepatocytes with 40 μM DIDS and/or 5 μM DDP for 72 h to investigate the effects of DIDS on DDP-induced hepatocyte apoptosis. With Annexin V-FITC/PI detection, the rate of apoptosis significantly increased in the DDP group compared with the control group; however, cells treated with the combination of DDP and DIDS displayed significant decreased rates of apoptosis compared with the DDP group (P < 0.05, Fig. 1A,B). Additionally, the protein expression levels of cleaved caspase-3, a marker of apoptosis, significantly decreased in DDP- and DIDS-treated group compared with the DDP group (P < 0.05, Fig. 1C,D). These results presented that DIDS antagonized DDP-induced apoptosis in L-02 hepatocytes.

**DIDS inhibited DDP-induced mitochondrial oxidative stress in L-02 hepatocytes**

The mitochondrial electron transport chain is the major intracellular source of ROS, including O2•−, hydroxyl radical, and various peroxides and hydroperoxides. To assess the mitochondrial oxidative stress in L-02 hepatocytes, ROS and O2•− generation were detected using the DCFH-DA probe and the MitoSOX Red probe, respectively. ROS and O2•− generation increased significantly in the DDP group, compared with the control group. However, ROS and O2•− generation significantly decreased in DDP- and DIDS-treated group compared with the DDP group (P < 0.05, Fig. 2A,B). These results presented that DIDS inhibited DDP-induced mitochondrial oxidative stress in L-02 hepatocytes.

**DIDS alleviated DDP-induced DNA damage in L-02 hepatocytes**

DNA double-strand breaks were measured using the neutral comet assay. The larger the comet tail, the more DNA damage has occurred. The comet tail length significantly increased in the DDP group compared with the control group; however, the group treated by DDP and DIDS in combination displayed significant decreased comet tail length compared with the DDP group (P < 0.05, Fig. 3A,B). Additionally, the protein expression levels of γH2AX, as an early marker of the DNA damage response, significantly increased in the DDP group compared with the control group; however, the expression of γH2AX level significantly decreased in DDP- and DIDS-treated group compared with the DDP group (P < 0.05, Fig. 3C,D). These results presented that DIDS alleviated DDP-induced DNA damage in L-02 hepatocytes.

**DIDS rescued DDP-induced impaired mitochondrial respiration chain in L-02 hepatocytes**

COXI is the largest mitochondrial respiratory chain complex and is the entry point for electrons into the
respiration chain. COXI activity was determined by following the oxidation of NADH to NAD$^+$ and the simultaneous reduction of the provided dye which leads to increased absorbance at OD 450 nm. We found that COXI activity was significantly suppressed in DDP-treated cells compared with NC cells, while DIDS antagonized the effects of DDP ($P < 0.05$, Fig. 4).

Considering the enzyme activity was also influenced by enzyme content, we also detected the protein level of representative COXI subunit NDUFB protein [15]. Western blot analysis showed no significant difference in NDUFB6 protein level among different treatment groups, which indicated that DIDS rescued the decrease of mitochondria respiratory activity under DDP exposure.

Discussion

In this study, DIDS, as an inhibitor of VDAC1 oligomerization, reduced the DDP-induced increase of $O_2^{-}$ release and ROS generation and alleviated comet tail length and increase of γH2AX protein. DNA damage and mitochondrial respiratory chain COXI activity protection by DIDS, gave rise to inhibition of DDP-induced activation of caspase 3 and hepatocytes apoptosis.

VDAC1 oligomerization inhibitors DIDS inhibited DDP-induced apoptosis in L-02 hepatocytes.
which indicated VDAC1 oligomerization might be a major target in DDP-induced hepatocytes apoptosis. In previous studies, DIDS has been shown to antagonize apoptosis. Liu AH et al. demonstrated that DIDS attenuated staurosporine-induced cardiomyocyte apoptosis by PI3K/Akt signaling pathway [16]. DIDS inhibits overexpression BAK1-induced mitochondrial apoptosis through GSK3β/β-catenin signaling pathway [17].

In the present study, we focused on the role of DIDS in DDP-induced mitochondrial damage and apoptosis. Mitochondria are the regulatory centers of cellular energy metabolism and mainly targeted to induced apoptosis [18]. Functional impairment of mitochondria due to inhibition of respiratory chain complexes increases the electrons leakage from electron transport chain and promotes the production of ROS, causing oxidative stress [19]. DIDS antagonized quinocetone induces apoptosis in HepG2 cells by alleviated cellular oxidative stress [20]. VDAC1 is located in the outer membrane of mitochondria and constitutes a protein channel for the transport of metabolites between the mitochondria and cytoplasm [21]. It was found that VDAC1 oligomerization promoted ROS to be released from the mitochondria to the cytoplasm through VDAC1 channel, resulting in the expansion of oxidative damage cascade [22]. Feng et al. found that iron death inhibitors protected cardiomyocytes by reducing VDAC1 oligomerization and mitochondrial ROS generation [23]. We also found that intervention of VDAC1 oligomerization by DIDS...
significantly decreased ROS and $O_2^{-}$ release after DDP treatment, suggesting that VDAC1 oligomerization might promote oxidative damage by increasing electron leakage out from mitochondria.

Moreover, DDP can directly attack DNA to form DNA adduct, while mitochondrial DNA encodes 13 proteins that are essential subunits of mitochondrial respiratory chain complexes. DNA oxidative damage of mitochondrial further leads to dysfunction of mitochondrial respiratory chain complex, affecting electron transport and energy production [24]. In this study, DIDS alleviated DDP-induced DNA damage and COXI activity decreased in hepatocytes, suggesting that VDAC1 oligomerization might promote DDP-induced mtDNA damage and subsequently mitochondrial respiratory chain complex impairment. DIDS alleviated DNA damage induced by T-2 toxin in human gastric epithelium GES-1 cells by inhibiting VDAC1 oligomerization [25]. Kim et al. also found that damaged mtDNA broke into fragments, which stimulated VDAC1 oligomerization form mitochondrial pores to release mtDNA fragments into the cytoplasm, thus aggravating mitochondrial damage [26]. It is reasonable to deduce that DDP-induced VDAC1 oligomerization promoted mtDNA leakage out of mitochondria, which aggravated mtDNA damage. Meanwhile, mtDNA leakage after DDP exposure affected respiratory chain complex activity encoded by mtDNA and further promoted electrons leakage and mitochondrial oxidative damage.

In conclusion, this study found that DDP might elevate VDAC1 oligomerization, which promoted ROS and mtDNA to be released from the mitochondria to the cytoplasm through VDAC1 channel, resulting in the expansion of mitochondrial oxidative stress and DNA damage. DIDS, an inhibitor of VDAC1 oligomerization, can alleviate DDP-induced mitochondrial oxidative stress, DNA damage, and cell apoptosis in L-02 hepatocytes, which provide scientific evidence for alleviating liver injury in patients undergoing chemotherapy.

**Conflict of interest**

The authors declare no conflict of interest.

**Authors’ contributions**

LL conceived the idea of the study. XQZ analyzed most of the data and wrote the initial draft of the paper. YX and YL performed the research and reviewed the manuscript. The remaining authors contributed to the collection of data. All authors read and approved the final manuscript.

**Data accessibility**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**References**

1. Urdzik J, Vildhede A, Wiśniewski JR, Duraj F, Haglund U, Artursson P, et al. Global proteome changes in liver tissue 6 weeks after FOLFOX treatment of colorectal cancer liver metastases. *Proteomes*. 2016; 4:30.
2. Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in toxicological research of the anticancer drug cisplatin. *Chem Res Toxicol*. 2019; 32:1469–86.
3. Yu S, Yan X, Tian R, Xu L, Zhao Y, Sun L, et al. An Experimentally induced mutation in the UBA domain of p62 changes the sensitivity of cisplatin by up-regulating hk2 localisation on the mitochondria and increasing mitophagy in A2780 ovarian cancer cells. *Int J Mol Sci*. 2021; 22:3983.
4. El-Shitany NA, Eid B. Proanthocyanidin protects against cisplatin-induced oxidative liver damage through inhibition of inflammation and NF-$\kappa$B/TLR-4 pathway. *Environ Toxicol*. 2017; 32:1952–63.
5. Ekinci-Akdemir RF, Bi Ngöl C, Yıldırım S, Kandemi RF, Küçükler S, Sağlam YS. The investigation of the effect of fraxin on hepatotoxicity induced by cisplatin in rats. *Iran J Basic Med Sci*. 2020; 23:1382–7.
6. Abd Rashid N, Hussan F, Hamid A, Adib Ridzuan NR, Halim S, Abdul Jalil NA, et al. Polygonum minus essential oil modulates cisplatin-induced hepatotoxicity through inflammatory and apoptotic pathways. *Excli J*. 2020; 19:1246–65.
7. Bilge Y, Akbulut S, Aksungur Z, Erdemli ME, Ozhan O, Parlakpinar H, et al. Protective effect of dexamethasone against cisplatin-induced hepatotoxicity. *Exp Ther Med*. 2018; 16:4049–57.
8. Magri A, Reina S, De Pinto V. VDAC1 as pharmacological target in cancer and
neurodegeneration: focus on its role in apoptosis. Front Chem. 2018;6:108.
9 Shoshan-Barmatz V, Keinan N, Abu-Hamad S, Tyomkin D, Aram L. Apoptosis is regulated by the VDAC1 N-terminal region and by VDAC oligomerization: release of cytochrome c, AIF and Smac/Diablo. Biochim Biophys Acta. 2010;1797:1281–91.
10 Keinan N, Tyomkin D, Shoshan-Barmatz V. Oligomerization of the mitochondrial protein voltage-dependent anion channel is coupled to the induction of apoptosis. Mol Cell Biol. 2010;30:5698–709.
11 Ben-Hail D, Shoshan-Barmatz V. VDAC1-interacting anion transport inhibitors inhibit VDAC1 oligomerization and apoptosis. Biochim Biophys Acta. 2016;1863:1612–23.
12 Thinnes FP, Flörke H, Winkelbach H, Stadtmüller U, Heiden M, Karabinos A, et al. Channel active mammalian porin, purified from crude membrane fractions of human B lymphocytes or bovine skeletal muscle, reversibly binds the stilbene-disulfonate group of the chloride channel blocker DIDS. Biol Chem Hoppe Seyler. 1994;375:315–22.
13 Luo L, Xiong Y, Jiang N, Zhu X, Wang Y, Lv Y, et al. VDAC1 as a target in cisplatin anti-tumor activity through promoting mitochondria fusion. Biochem Biophys Res Commun. 2021;560:52–8.
14 Viera T, Patidar PL. DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition. Sci Rep. 2020;10:20210.
15 Varuzhanyan G, Rojansky R, Sweredoski MJ, Graham RL, Hess S, Ladinsky MS, et al. Mitochondrial fusion is required for spermatogonial differentiation and meiosis. Elife. 2019;8.
16 Liu AH, Cao YN, Liu HT, Zhang WW, Liu Y, Shi TW, et al. DIDS attenuates staurosporine-induced cardiomyocyte apoptosis by PI3K/Akt signaling pathway: activation of eNOS/NO and inhibition of Bax translocation. Cell Physiol Biochem. 2008;22:177–86.
17 Yang X, Tang S, Li D, Yu X, Wang F, Xiao X. DIDS inhibits overexpression BAK1-induced mitochondrial apoptosis through GSK-3β/β-catenin signaling pathway. J Cell Physiol. 2018;233:5070–7.
18 Garza-Lombó C, Pappa A, Panayiotidis MI, Franco R. Redox homeostasis, oxidative stress and mitophagy. Mitochondrion. 2020;51:105–17.
19 Picca A, Calvani R. Cell death and inflammation: the role of mitochondria in health and disease. Cells. 2021;10:537.
20 Yang X, Tang S, Dai C, Li D, Zhang S, Deng S, et al. Quinocetone induces mitochondrial apoptosis in HepG2 cells through ROS-dependent promotion of VDAC1 oligomerization and suppression of Wnt1/β-catenin signaling pathway. Food Chem Toxicol. 2017;105:161–76.
21 Shoshan-Barmatz V, Pittala S, Mizrachi D. VDAC1 and the TSPO: expression, interactions, and associated functions in health and disease states. Int J Mol Sci. 2019;20:3348.
22 Gatliff J, East D, Crosby J, Abeti R, Harvey R, Craigen W, et al. TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control. Autophagy. 2014;10:2279–96.
23 Feng Y, Madungwe NB, Imam Aliagan AD, Tombo N, Bopassa JC. Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels. Biochem Biophys Res Commun. 2019;520:606–11.
24 Indo HP, Davidson M, Yen HC, Suenaga S, Tomita K, Nishi T, et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion. 2007;7:106–18.
25 Su N, Liu CL, Chen XP, Fan XX, Ma YC. T-2 toxin cytotoxicity mediated by directly perturbing mitochondria in human gastric epithelium GES-1 cells. J Appl Toxicol. 2020;40:1141–52.
26 Kim J, Gupta R, Blanco LP, Yang S, Shteinfehr-Kuzmine A, Wang K, et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science. 2019;366:1531–6.